A newly developed human papillomavirus (HPV) vaccine, produced using Escherichia coli, has demonstrated effectiveness in protecting women against cancer-causing HPV strains. Published in The Lancet Infectious Diseases, this study suggests that the E coli-produced HPV vaccine offers a more affordable alternative to currently available vaccines. This cost reduction holds significant potential for increasing immunization rates, particularly in low- to middle-income countries.
Researchers involved in the study, led by the Jiangsu Provincial Academy of Preventative Medicine in China, noted that the vaccine’s lower production cost could significantly improve global access to high-valency HPV vaccination.
Effective Protection Against High-Risk HPV Strains
HPV is responsible for approximately 90% of cervical cancer cases, making it the fifth most common cancer among women globally. The World Health Organization (WHO) reported that in 2024, 604,000 women were diagnosed with cervical cancer, and 280,000 died from the disease, with a disproportionate number of these deaths occurring in less affluent nations.
The WHO has set an ambitious goal to eliminate cervical cancer by ensuring 90% of girls worldwide are vaccinated by 2030. However, the high cost of existing vaccines presents a substantial barrier for many countries seeking to implement widespread HPV immunization programs.
A multicenter, double-blind, randomized clinical trial involving 9,327 unvaccinated women in China was conducted to assess the protective capabilities of the E coli-produced nine-valent (9vHPV) HPV vaccine. In the trial, 4,664 participants received the 9vHPV vaccine, known as Cecolin 9, while the remaining 4,663 women received the two-valent HPV vaccine, Cecolin, as a control.
The findings revealed that Cecolin 9 was highly effective, demonstrating 98.2% efficacy in preventing infection for a 12-month period from several high-risk HPV strains, including types 31, 33, 45, 52, and 58.
In an accompanying commentary, Punnee Pitisuttihum, PhD, from Mahidol University in Thailand, and Rakesh Aggarwal, MD, DM, from Mahatma Gandhi University of Medical Science and Technology in India, highlighted the significance of these efficacy results, stating, "The efficacy results of Cecolin 9 against the 12-month persistent infection is an important milestone." They also pointed out the ongoing challenge of securing licensing for the product outside of China and the necessity of seeking WHO prequalification to confirm that Cecolin 9 adheres to global safety standards.